a Department of Biotherapy , Cancer Research Institute, The First Affiliated Hospital of China Medical University , Shenyang , China.
b Key Laboratory of Ministry of Education for TCM Viscera-State Theory and Applications , Liaoning University of Traditional Chinese Medicine , Shenyang , China.
Drug Deliv. 2018 Nov;25(1):690-702. doi: 10.1080/10717544.2018.1444684.
Pingyangmycin (PYM) has been applied clinically for many years to treat vascular malformations (VM) in China. The major limitation of PYM injections is quick diffusion from the injection site, which increases side effects, especially the possibility of pulmonary injury. In this paper, chitosan/glycerophosphate disodium (CS/GP) thermogels containing liposomes for sustained and localized PYM delivery were prepared and optimized by a three-level three-factorial Box-Behnken experimental design to evaluate the effects of different variables (the PYM concentration, CS amount and GP content), on the selected responses (cumulative percentage PYM released in 1 day, 9 days and the rate constant k). The results revealed that the optimized PYM liposomal thermogels had a controlled PYM release for 14 days in vitro, which confirmed the validity of optimization. In vitro morphological observation, cell cycle and apoptosis analysis showed an effective anti-proliferation action of PYM liposomal thermogels on human vascular endothelial cells (EA.hy926). In vivo pharmacokinetics research in rabbits displayed that compared with PYM liposomes and PYM thermogels, PYM liposomal thermogels had a better controlled delivery of PYM. Histological examination of rabbit ear veins showed that after local application with PYM lipsomal thermogels for 21 days, obvious vein thrombosis and inflammatory reaction could be observed. The above results indicated that PYM-loaded lipsomal CS/GP thermogels might have a good prospect for the treatment of VM.
平阳霉素(PYM)已在中国临床应用多年,用于治疗血管畸形(VM)。PYM 注射的主要局限性是从注射部位迅速扩散,这会增加副作用,特别是肺损伤的可能性。本文制备了载有脂质体的壳聚糖/甘油磷酸二钠(CS/GP)温敏凝胶,通过三水平三因素 Box-Behnken 实验设计优化,考察不同变量(PYM 浓度、CS 量和 GP 含量)对选择响应(1 天、9 天和速率常数 k 累积释放的 PYM%)的影响。结果表明,优化后的 PYM 脂质体温敏凝胶具有体外控制 PYM 释放 14 天的能力,证实了优化的有效性。体外形态观察、细胞周期和凋亡分析表明,PYM 脂质体温敏凝胶对人血管内皮细胞(EA.hy926)具有有效的抗增殖作用。兔体内药代动力学研究显示,与 PYM 脂质体和 PYM 温敏凝胶相比,PYM 脂质体温敏凝胶具有更好的 PYM 控制释放。兔耳静脉局部应用 PYM 脂质体温敏凝胶 21 天后的组织学检查显示,可观察到明显的静脉血栓形成和炎症反应。上述结果表明,载 PYM 脂质体 CS/GP 温敏凝胶可能是治疗 VM 的一种有前景的方法。